These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21972078)

  • 1. Alu in Lynch syndrome: a danger SINE?
    Hitchins MP; Burn J
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1527-30. PubMed ID: 21972078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence and variability of germline EPCAM deletions in Lynch syndrome.
    Kuiper RP; Vissers LE; Venkatachalam R; Bodmer D; Hoenselaar E; Goossens M; Haufe A; Kamping E; Niessen RC; Hogervorst FB; Gille JJ; Redeker B; Tops CM; van Gijn ME; van den Ouweland AM; Rahner N; Steinke V; Kahl P; Holinski-Feder E; Morak M; Kloor M; Stemmler S; Betz B; Hutter P; Bunyan DJ; Syngal S; Culver JO; Graham T; Chan TL; Nagtegaal ID; van Krieken JH; Schackert HK; Hoogerbrugge N; van Kessel AG; Ligtenberg MJ
    Hum Mutat; 2011 Apr; 32(4):407-14. PubMed ID: 21309036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPCAM germline and somatic rearrangements in Lynch syndrome: identification of a novel 3'EPCAM deletion.
    Spaepen M; Neven E; Sagaert X; De Hertogh G; Beert E; Wimmer K; Matthijs G; Legius E; Brems H
    Genes Chromosomes Cancer; 2013 Sep; 52(9):845-54. PubMed ID: 23801599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
    Li L; McVety S; Younan R; Liang P; Du Sart D; Gordon PH; Hutter P; Hogervorst FB; Chong G; Foulkes WD
    Hum Mutat; 2006 Apr; 27(4):388. PubMed ID: 16541406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Japanese Lynch syndrome patient with large deletion in the 3' region of the EPCAM gene.
    Eguchi H; Kumamoto K; Suzuki O; Kohda M; Tada Y; Okazaki Y; Ishida H
    Jpn J Clin Oncol; 2016 Feb; 46(2):178-84. PubMed ID: 26613680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome.
    Kloor M; Voigt AY; Schackert HK; Schirmacher P; von Knebel Doeberitz M; Bläker H
    J Clin Oncol; 2011 Jan; 29(2):223-7. PubMed ID: 21115857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification.
    Musulen E; Blanco I; Carrato C; Fernandez-Figueras MT; Pineda M; Capella G; Ariza A
    Hum Pathol; 2013 Mar; 44(3):412-6. PubMed ID: 23026194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.
    Mur P; Pineda M; Romero A; Del Valle J; Borràs E; Canal A; Navarro M; Brunet J; Rueda D; Ramón Y Cajal T; Lázaro C; Caldés T; Blanco I; Soto JL; Capellá G
    Clin Genet; 2014 Mar; 85(3):260-6. PubMed ID: 23530899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
    Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
    Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.
    Guarinos C; Castillejo A; Barberá VM; Pérez-Carbonell L; Sánchez-Heras AB; Segura A; Guillén-Ponce C; Martínez-Cantó A; Castillejo MI; Egoavil CM; Jover R; Payá A; Alenda C; Soto JL
    J Mol Diagn; 2010 Nov; 12(6):765-70. PubMed ID: 20864635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.
    Rumilla K; Schowalter KV; Lindor NM; Thomas BC; Mensink KA; Gallinger S; Holter S; Newcomb PA; Potter JD; Jenkins MA; Hopper JL; Long TI; Weisenberger DJ; Haile RW; Casey G; Laird PW; Le Marchand L; Thibodeau SN
    J Mol Diagn; 2011 Jan; 13(1):93-9. PubMed ID: 21227399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of a novel alu-mediated deletion.
    Duraturo F; Cavallo A; Liccardo R; Cudia B; De Rosa M; Diana G; Izzo P
    Biomed Res Int; 2013; 2013():219897. PubMed ID: 23484096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors.
    Huth C; Kloor M; Voigt AY; Bozukova G; Evers C; Gaspar H; Tariverdian M; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Mod Pathol; 2012 Jun; 25(6):911-6. PubMed ID: 22388758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPCAM deletions, Lynch syndrome, and cancer risk.
    Lynch HT; Lynch JF; Snyder CL; Riegert-Johnson D
    Lancet Oncol; 2011 Jan; 12(1):5-6. PubMed ID: 21195320
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of novel, large duplications in the MSH2 gene of three unrelated Lynch syndrome patients.
    Liccardo R; De Rosa M; Rossi GB; Rigler G; Izzo P; Duraturo F
    Cancer Genet; 2018 Feb; 221():19-24. PubMed ID: 29405992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
    van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
    Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.